Several ongoing trials are evaluating incretin-based therapies, including GLP-1 receptor agonists, for their effects on CKD and MASLD. These studies will offer insights into their potential for metabolic diseases in people with type 2 diabetes and obesity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jdi.14336 | DOI Listing |
Publication Analysis
Top Keywords
type diabetes
8
diabetes obesity
8
incretin hormones
4
hormones revolutionizing
4
revolutionizing treatment
4
treatment landscape
4
landscape kidney
4
kidney liver
4
liver diseases
4
diseases type
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!